Astrogen, inc.
- Company typePrivate
- Founded2017
- HeadquartersDaegu, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
Astrogen, inc. firmographics
Firmographics- Name
- Astrogen, inc.
- Legal name
- (주)아스트로젠
- Website
- https://astrogen.co.kr
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Astrogen, inc. industry classification
Industry- Product category
- CNS Pharmaceutical Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Astrogen, inc. is headquartered
LocationHeadquarters
- HQ city
- Daegu
- HQ country
- South Korea
- HQ region
- Asia
Offices4 records
Markets served
Astrogen, inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Product Supply Revenue: Direct revenue from supplying AST-001 (Speragen) drug product. The Middle East deal includes $131 million for product supply with an additional $77.5 million upon Korean regulatory approval, plus double-digit royalties on future sales.
- Technology Transfer and Licensing: Revenue from technology transfer deals including the $208.5 million deal with Cigalah Medpharm for exclusive commercialization rights in 16 MENA countries. Includes milestone payments and ongoing royalties.
- Royalty Income: Double-digit royalties on future product sales in Middle East markets through the Cigalah Medpharm partnership.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Astrogen, inc. product offering
Product offeringCore offering
Astrogen, Inc. is a clinical-stage pharmaceutical company developing small-molecule therapies for neurological and rare diseases. Its lead candidate Speragen (AST-001) is an oral syrup for autism spectrum disorder (ASD) targeting core social communication symptoms via SK channel regulation and dopamine signaling normalization. The pipeline also addresses Alzheimer's, Parkinson's, stroke, traumatic brain injury, and glioblastoma.
Product overview
Astrogen is a clinical-stage pharmaceutical company developing treatments for intractable neurological disorders. Its core product is Speragen (AST-001), an oral syrup for autism spectrum disorder core symptoms, which completed Phase 3 trials with NDA submitted in Korea in June 2025 and a $208.5M technology transfer deal signed for 16 MENA countries. The pipeline spans multiple neurological indications: AST-002 (traumatic brain injury, Phase 1 pending), AST-011 (Alzheimer’s, preclinical with K-Medihub), AST-029 (Parkinson’s, AI-designed with IKTOS, preclinical), AST-009 (Parkinson’s, peptide, preclinical), AST-025 (stroke, preclinical), AST-003 (ASD for global transfer, preclinical), and AST-035A (anticancer, molecular glue for glioblastoma, preclinical). The company also operates Stellar Steps, a social program providing free ADL training for adolescents with developmental disabilities.
Differentiator
Problem solved
Functional benefit
Brands
- 스텔라 스텝스 (Stellar Steps): A self-help and independence education program for adolescents with autism and developmental disabilities, operated as part of Astrogen's ESG social contribution activities.
- 스페라젠 (Speragen)
Products and services
- Speragen (AST-001) Oral syrup drug candidate for treating core symptoms of autism spectrum disorder (ASD) in children ages 2 and older. Targets social communication deficits and restricted/repetitive behaviors via synaptic pruning activation and dopamine signal normalization through SK channel regulation. NDA submitted to Korean MFDS in June 2025.
- AST-002 Injectable drug candidate for traumatic brain injury and cerebrovascular disease treatment. Reformulated existing drug with new indication, with Phase 1 IND application under preparation.
- AST-011 (Alzheimer's disease treatment) Low-molecule compound for Alzheimer's disease treatment, currently in preclinical stage. Jointly developed with K-Medihub and targeting clinical Phase 1 entry.
- AST-029 (Parkinson's disease treatment) Parkinson's disease drug candidate targeting a specific mutated gene variant. Developed in collaboration with France-based IKTOS using AI-driven compound design. Currently in preclinical stage.
- AST-009 (Parkinson's disease treatment) Peptide compound for Parkinson's disease treatment, in candidate substance identification stage. Part of the broader Parkinson's pipeline alongside AST-029.
- AST-025 (Stroke treatment) Innovative new drug candidate for stroke treatment, currently in candidate substance derivation stage.
- AST-003 (ASD treatment, global target) Autism spectrum disorder treatment candidate in preclinical stage, positioned for global technology transfer (not self-clinical development).
- AST-035A (Glioblastoma treatment) Next-generation anticancer drug candidate based on molecular glue technology, targeting glioblastoma as primary indication with potential expansion to liver cancer and other treatment-resistant cancers. In preclinical stage with IND preparation underway in collaboration with DTCRO.
Quantifiable outcome
- Social adaptability improved in 61% at 12 weeks and 78% at 24 weeks in high-dose group based on Vineland Adaptive Behavior Composite scores
- +4 more outcomes
Companies that use Astrogen, inc.
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Astrogen, inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature3 records
Astrogen, inc. partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, minor and major.
- Cigalah Medpharm Trading LLCcoreExclusive technology transfer and commercialization partnership for Speragen (AST-001) covering 16 countries in Middle East and North Africa. Deal valued at $208.5 million including $131M product supply, $77.5M upon Korean regulatory approval, plus double-digit royalties on future sales. Cigalah is the largest healthcare distribution group in MENA region with #1 market position in Saudi Arabia SFDA registered products.
- HoneyistminorJoint development of customized oral care products for children with ASD. 'Bubble Gargle' product being developed for children with sensory sensitivity who struggle with toothbrushing. Astrogen provides clinical research data and medical insights; Honeyist provides formulation development and safety testing.
- Korean Society of Pediatric and Adolescent Behavioral Development (대한소아청소년 행동발달증진학회)minorMOU for improving treatment systems for developmental disorders, strengthening medical professional education, social awareness promotion, and policy recommendations. Society committed to supporting Speragen market adoption upon approval.
- DT&CROminorPreclinical and clinical CRO partnership for next-generation anticancer drug candidate AST-035A development. AST-035A uses molecular glue technology targeting glioblastoma. DT&CRO provides clinical trial design and research support for global market entry.
- Nexpharm KoreamajorStrategic partnership for GMP manufacturing of AST-001 Phase 3 clinical trial materials. Nexpharm Korea provides pharmaceutical production facilities meeting global GMP standards. Partnership expanded from Phase 2 collaboration following successful clinical trial completion.
- Kemedihub (대구경북첨단의료산업진흥재단)majorMulti-faceted partnership including drug development cooperation, GMP production, and digital healthcare device development. Astrogen's lead pipeline AST-001 manufactured at Kemedihub facilities. Joint research on Parkinson's disease and cerebellar atrophy treatments. Also collaborated with NewDive on ASD digital therapeutic development.
- Agarson BiomajorAPI (active pharmaceutical ingredient) supply partnership for AST-001 Phase 3 clinical trials. Agarson Bio supplies raw materials for clinical trial production and will support overseas production capacity for international commercialization.
- Daegu Fatima HospitalminorHealthcare joint research MOU for clinical trial cooperation, health promotion services, and business collaboration. Fatima Medical Research Institute partnership for mutual research system establishment.
- IKTOS (France)coreAI-powered drug discovery collaboration for Parkinson's disease treatment. IKTOS provides novel compound design and optimization using active learning-based structure generation modeling. Astrogen handles efficacy verification, preclinical, and clinical development. First Korean partnership for IKTOS in the biopharmaceutical sector.
- J2H BiotechmajorJoint development partnership for degenerative brain diseases and nervous system disorders. J2H Biotech provides drug design, synthesis, and CMC capabilities; Astrogen handles efficacy evaluation, formulation development, and clinical strategy. Partnership leverages complementary strengths in CNS drug development.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Astrogen, inc. competitors and assessment
Company assessmentDirect peers
- Curemark: Curemark is a clinical-stage biopharmaceutical company developing CM-AT for the treatment of autism spectrum disorder, making it one of the few direct peers pursuing a pharmacological therapy for pediatric ASD core symptoms.
- Yamo Pharmaceuticals: Yamo Pharmaceuticals is developing L-1-methylfolate for autism spectrum disorder and is a direct competitor in the same target indication (ASD) and patient population.
- PaxMedica: PaxMedica is a clinical-stage pharmaceutical company developing suramin for neurodevelopmental disorders including autism, with overlapping CNS/rare disease focus and similar pre-commercial stage.
- Marinus Pharmaceuticals: Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders and is comparable as a small-cap clinical-to-commercial CNS specialty company with similar regulatory pathway dynamics.
Broad incumbents
- Hanmi Pharmaceutical: Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a significant CNS and rare disease franchise, comparable as a much larger domestic incumbent with overlapping therapeutic categories.
- BioMarin Pharmaceutical: BioMarin Pharmaceutical is a global rare disease specialist with established orphan drug commercialization capabilities, comparable in business model and regulatory pathway to Astrogen's Speragen program.
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty CNS pharmaceutical company with rare neurology assets, comparable as an established player that built commercial CNS franchises through licensing and acquisition.
- Supernus Pharmaceuticals: Supernus Pharmaceuticals is a specialty CNS company focused on neurology and psychiatry products, comparable as a US-listed CNS-focused specialty pharma with established commercial infrastructure.
Regional players
- Yuhan Corporation: Yuhan Corporation is one of Korea's largest pharmaceutical companies with CNS and rare disease programs, comparable as a domestic Korean pharmaceutical incumbent and potential commercial partner for Astrogen.
Others
- IKTOS: IKTOS is a French AI-driven drug discovery company and Astrogen's technology partner for Parkinson's pipeline development, comparable as a collaborator/ecosystem participant rather than direct competitor.
Market position
Strengths5 records
Weaknesses6 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Astrogen, inc. social profiles
Digital presenceAstrogen, inc. compliance and trust
Trust signalCompliance7 records
Astrogen, inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Astrogen, inc. leadership team
Management profileNumber of profiles
Profiles4 records
Astrogen, inc. funding detail
Funding detailFunding overview
Funding rounds4 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Astrogen, inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Astrogen, inc.
What does Astrogen, inc. do?
Astrogen, Inc. is a clinical-stage pharmaceutical company developing small-molecule therapies for neurological and rare diseases. Its lead candidate Speragen (AST-001) is an oral syrup for autism spectrum disorder (ASD) targeting core social communication symptoms via SK channel regulation and dopamine signaling normalization. The pipeline also addresses Alzheimer's, Parkinson's, stroke, traumatic brain injury, and glioblastoma.
Is Astrogen, inc. a public or private company?
Astrogen, inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was Astrogen, inc. founded?
Astrogen, inc. was founded in 2017. It employs 11 to 50 people.
Where is Astrogen, inc. based?
Astrogen, inc. is headquartered in Daegu, South Korea, in the Asia region.
How does Astrogen, inc. make money?
Three revenue lines are on record. Product Supply Revenue is the primary driver. The others are technology Transfer and Licensing and royalty Income.
Who are Astrogen, inc.'s main competitors?
Direct peers on record are Curemark, Yamo Pharmaceuticals, PaxMedica and Marinus Pharmaceuticals. Broad incumbents are Hanmi Pharmaceutical, BioMarin Pharmaceutical, Jazz Pharmaceuticals and Supernus Pharmaceuticals. Yuhan Corporation is listed as a regional player. IKTOS is listed as an others.
Does Astrogen, inc. have an API?
No public API is recorded for Astrogen, inc..
What industry is Astrogen, inc. in?
Astrogen, inc.'s product category is CNS Pharmaceutical Development. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.